Omrix Biopharmaceuticals

About

Omrix Biopharmaceuticals specializes in the development and manufacture of products derived from human plasma. The products are based on patented technology and sold throughout the world. The company's biosurgical line includes hemostatic products designed to control bleeding during surgery. Omrix also makes a line of passive immunotherapy products for patients with immune deficiencies. Omrix operates as part of Johnson & Johnson's Medical Device and Diagnostics Sector, reporting through Ethicon Inc. The company's facilities include a production plant at Tel Hashomer Hospital, a biomanufacturing facility in Har-Hozvim Technology Park, Jerusalem, and an R&D facility located in the Weizmann Science Park of Ness Ziona.

Facts

Funding rounds (1)

Acquisitions (1)

Public offerings (1)

Team (2)

News mentions (1)

1. Nov 23, 2008 — www.globes.co.il: Article